DayTwo is the global leader in microbiome-based precision medicine and has the largest actionable microbiome database worldwide. Founded in 2014 from original research at the Weizmann Institute of Science, DayTwo released its first product for Glycemic Control in 2016. DayTwo’s US Clinical Partner, The Mayo Clinic, validated the science in 2017 and published in the journal JAMA earlier this year. The company’s product pipeline is fueled by the DayTwo Human Discovery Platform® and is focused on the development of new health and prevention products and services to address type II diabetes, prediabetes, metabolic syndrome, gastro-intestinal ailments, and, in addition, to create a lead-discovery database and tool-set for pharmaceutical, therapeutic, and biological discovery.